Legal and ethical challenges in AI-driven clinical trials
Clinical trials are a key area in which the use of AI in healthcare data has seen significant growth, yet…
All articles by GlobalData
GlobalData
@globaldataplc
-
-
Blood matching tests by the NHS may improve blood transfusion outcomes
According to the National Institute for Health and Care Excellence (NICE), sickle cell disease, a group of inherited diseases that…
-
Is raising mental health awareness causing more harm than good?
While raising mental health awareness is undoubtedly a positive step towards reducing stigma and promoting open conversations about mental health,…
-
Risk of chronic conditions associated with heavy alcohol intake in Chinese men
Controlled alcohol consumption does not pose any immediate danger to the public’s general health; however, excessive and persistent drinking can…
-
BioCardia submits Japan application for CardiAMP to treat ischemic HFrEF
BioCardia recently announced that it had submitted its leading product, CardiAMP, to Japan’s Pharmaceuticals and Medical Devices Agency (PMDA). CardiAMP…
-
Artificial intelligence advances cancer diagnostics in the next decade
In GlobalData’s Clinical Trials Database, there are currently 1,490 active clinical trials for in vitro diagnostics (IVD) devices, where 569…
-
Tilsotolimod combo’s trial failure leaves refractory melanoma patients in limbo
Idera Pharmaceuticals has revealed that the Phase III, pivotal ILLUMINATE-301 trial of tilsotolimod in combination with Bristol Myers Squibb’s Yervoy…
-
Chinese checkpoint inhibitors are poised to change global IO markets
The Chinese Government’s significant R&D investments in recent years has resulted in the successful commercialisation and launch of several domestically…
-
Turning point: November marked by promising Covid-19 vaccine development data
With the global devastation of Covid-19 continuing into 2021, the month of November marks a turning point in the pandemic…
-
Jardiance fails to deliver in EMPERIAL trials for heart failure
Boehringer Ingelheim and Eli Lilly’s collaborative effort to secure Jardiance’s (empagliflozin’s) place in the heart failure (HF) landscape has reached…